	US 11,793,828 B2
	MicroRNA 19A/19B for use in treating a pathological condition associated with bone loss or reduced muscle function
Eric Hesse, Hamburg (DE); Hanna Taipaleenmäki, Hamburg (DE); and Hiroaki Saito, Puchheim (DE)
Assigned to UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF, Hamburg (DE)
Filed by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF, Hamburg (DE)
Filed on May 14, 2021, as Appl. No. 17/320,649.
Application 17/320,649 is a continuation of application No. 16/499,520, granted, now 11,013,755, previously published as PCT/EP2018/058828, filed on Apr. 6, 2018.
Claims priority of application No. 100182 (LU), filed on Apr. 6, 2017.
Prior Publication US 2021/0268014 A1, Sep. 2, 2021
Int. Cl. C12N 15/11 (2006.01); A61K 31/711 (2006.01); A61P 19/10 (2006.01); A61K 38/29 (2006.01)

CPC A61K 31/711 (2013.01) [A61K 38/29 (2013.01); A61P 19/10 (2018.01); C12Q 2525/207 (2013.01); C12Q 2600/178 (2013.01)]

7 Claims

1. A method of treating or preventing osteogenesis imperfecta (OI), cancer-related bone destruction caused by bone metastasis, muscle atrophy, cachexia or sarcopenia, said method comprising administering an inhibitor of microRNA 19a and/or microRNA 19b to a subject in need thereof, wherein said inhibitor is a nucleic acid or nucleic acid analog.